Ye Ethan Li, M.D., Ph.D.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
About Dr. Ye Ethan Li
The unique aspect of my work is the focus on the identification of treatment resistance of anti-cancer therapy and development of the novel strategy to overcome the therapeutic resistance and enhance treatment efficiency, as well as the translation the novel treatment strategies to the clinic, which centers on the expansion of immune cells for the purpose of immunotherapy. I have explored the understanding of the molecular etiology and immune response in the process of malignant transformation, applying cellular-based immune therapies to increase curative efficacy in treating cancer. Over my 10 years lab research experience in leading different scientific projects, I have succeed in accumulatively publishing research articles as the first author relevant to cancer biology (Oncotarget, 2017), cancer bioinformatics (Nutrient. 2021), and anti-cancer cellular therapy (Cell Stem cell, 2018; Nature Medicine, 2022; Nature Medicine 2024). With my current position, I gain more access to the clinical data and clinical data analyze that allows me to integrate the question found fresh from the bed to the solution in bench. I aim to investigate the understanding of biomarkers during malignant progression as well as their treatment resistance mechanism with advanced cellular therapeutic approaches in order to develop novel strategies to improve outcomes for patients with cancer.
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Stem Cell Transplantation Research, Cell Therapy Institute for Discovery and Innovation, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistance Professor, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas
Research Interests
Specifically, in the most recent 5 years, my research in advancing anti-tumor cellular therapy by using NK cells has achieved great impact on both healthcare industry and the field of anti-tumor cellular therapy and immunotherapy.
(i) Development of induced pluripotent stem cells (iPSCs)-derived natural killer (NK) cells with the expression of chimeric antigen receptors (CARs) that employ NK–specific activating signaling. The engineering of CARs may significantly enhance the anti-tumor activity of immune effector cells. NK cells have shown anti-tumor activity with no severe clinical toxicity. However, there is a lack of CAR signaling designated for optimizing NK activation. My research focuses on the re-construction of CAR signaling by employing NK-specific activation domains. Based on the cellular platform of iPSC-derived NK cells, I identified a CAR containing the transmembrane domain of NKG2D, the 2B4 co-stimulatory domain, and the CD3ζ signaling domain, which, together, mediates a strong antigen-specific NK cell response. In an ovarian cancer xenograft model, my work showed that NK-CAR-iPSC-NK cells significantly inhibited tumor growth, and prolonged survival compared with peripheral blood (PB)-NK cells, iPSC-NK cells, or T-CAR-iPSC-NK cells with less toxicity. These NK-CAR-iPSC-NK cells have been used in clinical trial as a type of "off-the-shelf" immune cell therapy in treating patients with B cell-derived (NCT04245722), which achieved in 74% response rate in treatment patients with B cell malignancies in the Phase I report. By the time of drafting this curriculum, the article describing my leading research entitled “Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity” has been cited for more than 500 times from peers of more than 50 institutes in 40 countries and territories,
(ii) Identification of trogocytosis (TROG) as a treatment resistance of CAR-NK cell-mediated antitumor therapy and the development of a novel dual-CAR system overcome the TROG-antigen-induced on-target off-tumor effects on CAR-NK cells, while sparing their on-target anti-tumor activity. In my study, I revealed a unique mechanism for tumor escape and treatment resistance following CAR-NK cell therapy; specifically that activation of activating CAR (aCAR) in NK cells drives the transfer of CAR-cognate antigen on NK cells from tumor cells that leads to NK cells fratricide and dysfunction. This phenomenon is associated with a concurrent loss of target antigen on the cancer cells, also rendering in tumor escape. Importantly, my designing of the novel dual-CAR strategy on NK cells that combines an extracellular domain targeting an NK-specific antigen with the signaling endodomain from an inhibitory KIR (iCAR) successfully that provides a “don't kill me” signaling, and achieves antigen-specific CAR-NK activation and cytotoxciity against tumor, but ignore the antigen expressing CAR-NK effector cells. This dynamic modulation of AI-CAR-signaling may find useful applications to improve the in vivo persistence and therapeutic efficacy of a range of adoptive NK cell therapies. As the first author, my manuscript entitled “KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape” was published in the highest-esteemed top-ranking journal of Nature Medicine, 2022. Tested in a phase I-II clinical trial using allogeneic umbilical cord-derived NK cells and genetically modified with CAR targeting at CD19-positve B cell-derived malignancies (NCT03056339), the higher TROG-antigen accumulation on CAR-NK cells significantly associated with non-responders of treatment and also contribute to the early tumor relapse, the strudy of which were published in Nature Medicine 2024. Both of my first author publication were selectively presenting in the “Wall of Science FY23Q1, FY24Q2” by MDACC.
Education & Training
Degree-Granting Education
| 2013 | Tongji Hospital Affiliated to Huazhong University of Science and Technology, Wuhan, Hubei, CN, Degree of Medicine |
| 2023 | MD Anderson Cancer Center, Houston, Texas, US, Ph.D |
| 2015 | Georgetown University Cancer Center, Washington, District of Columbia, US, Master Degree of Science |
Postgraduate Training
| 2023-2024 | Postgraduate Fellow, The University of Texas MD Anderson Cancer Center, Houston, Texas |
Experience & Service
Faculty Academic Appointments
Instructor, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2025
Editorial Activities
Frontiers Topic Editor, Collection of NK cell modifications to advance their anti-tumor activities, 2022 - Present
Guest Associate Editor, Frontiers in Oncology, 2022 - Present
Review Editor, Gene, 2022 - Present
Review Editor, NK and Innate Lymphoid Cell Biology of Frontiers in Immunology, 2022 - Present
Review Editor, Science Advance, 2022 - Present
Review Editor, Journal of Cellular and Molecular Medicine, 2022 - Present
Review Editor, Cancer Letter, 2022 - Present
Review Editor, Biomedicine and Pharmacotherapy, 2022 - Present
Review Editor, Cancer Immunity and Immunotherapy, 2019 - Present
Associate Editor, Frontiers Immunology, 2019 - Present
Honors & Awards
| 2025 - 2027 | ASTCT New Investigator Award |
| 2023 - Present | Thomas F. Burks Scholarship (Program Nominee) |
| 2022 - 2023 | CPRIT Graduate Training Grant |
| 2022 - 2023 | T.C. Hsu Memorial Scholarship |
| 2022 - 2023 | Schissler Foundation Fellowship (Relinquished) |
| 2022 | Regeneron Prize for Creative Innovation (MD Anderson Cancer Center Nominee) |
| 2021 - Present | Student InterCouncil (SIC) Positive Impact Scholarship |
| 2020 - 2021 | Andrew Sowell-Wade Huggins Scholarship in Cancer Research |
Professional Memberships
Grant & Contract Support
| Date: | 2027 - 2032 |
| Title: | Novel Cord Blood Cellular Therapies/Project 3 |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 2P01CA148600-12A/ FP00025328_Res1 |
| Date: | 2026 - 2030 |
| Title: | Development of Novel Engineered NK Cell Therapies for Relapsed or Refractory AML |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | R01CA299429_Res1 |
| Date: | 2025 - 2027 |
| Title: | American Society of Transplantation and Cellular Therapy (ASCTC) New Investigator Award (NIA) |
| Funding Source: | ASCTC |
| Role: | PI |
| Date: | 2023 - 2028 |
| Title: | Next-Generation Engineered NK Cell Immunotherapy for Ovarian Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1P50CA281701-01 |
Selected Publications
Peer-Reviewed Articles
- Olson A, Li YE, Basar R, Banerjee P, Kaur I, Abueg G, Sylejmani M, Uprety N, Shrestha R, Silva FR, Page V, Champlin RE, Kontoyiannis DP, Chemaly RF, Shpall EJ, Moore L, Gaber OA, Rezvani K, Abudayyeh A. Role of BK Virus CTLs in the Treatment of BK Virus-Associated Nephropathy in Kidney-Transplant and Hematopoietic Cell Transplant Recipients. Transpl Infect Dis 28(2):e70178, 2026. e-Pub 2026. PMID: 41645606.
- Biederstädt, A, Basar, R, Park, JM, Uprety, N, Shrestha, R, Reyes Silva, F, Dede, M, Watts, J, Acharya, S, Xiong, D, Liu, B, Daher, M, Rafei, H, Banerjee, PP, Li, P, Islam, S, Fan, H, Shanley, M, Jin, J, Kumar, B, Woods, V, Lin, P, Tiberti, S, Nunez Cortes, Ak, Jiang, XR, Biederstädt, I, Zhang, P, Li, YE, Rawal, S, Liu, E, Muniz-Feliciano, L, Deyter, GM, Shpall, E, Fowlkes, NW, Chen, K, Rezvani, K. Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potency. Cancer cell 43(11):2069-2088.e11, 2025. e-Pub 2025. PMID: 40845844.
- Rafei, H, Basar, R, Acharya, S, Hsu, YS, Liu, P, Zhang, D, Bohn, T, Liang, Q, Mohanty, V, Upadhyay, R, Li, P, Phadatare, P, Dede, M, Xiong, D, Fan, H, Jones, C, Kunz, S, Daher, M, Nunez Cortes, AK, Shanley, M, Liu, B, Moseley, SM, Zhang, C, Fang, D, Banerjee, PP, Uprety, N, Li, YE, Shrestha, R, Wan, X, Shen, H, Woods, V, Gilbert, AL, Rawal, S, Dou, J, Tan, Y, Park, JM, Reyes Silva, F, Biederstädt, A, Kaplan, M, Jiang, XR, Biederstädt, I, Kumar, B, Tiberti, S, Moore, M, Jin, J, Yang, RZ, Muniz-Feliciano, L, Rosemore, S, Lin, P, Deyter, GM, Fowlkes, NW, Jain, A, Marin, D, Maitra, A, Chen, K, Bopp, T, Shpall, E, Rezvani, K. CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Nature 643(8073):1076-1086, 2025. e-Pub 2025. PMID: 40468083.
- Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma. Nature medicine 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
- Melo Garcia, L, Gangadharan, A, Banerjee, PP, Li, YE, Zeng, A, Rafei, H, Lin, P, Kumar, B, Acharya, S, Daher, M, Muniz-Feliciano, L, Deyter, GM, Dominguez, G, Park, JM, Reyes Silva, F, Nunez Cortes, AK, Basar, R, Uprety, N, Shanley, M, Kaplan, M, Liu, E, Shpall, E, Rezvani, K. Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells. Cell Reports 44(1), 2025. e-Pub 2025. PMID: 39754720.
- Acharya, S, Basar, R, Daher, M, Rafei, H, Li, P, Uprety, N, Ensley, E, Shanley, M, Kumar, B, Banerjee, PP, Melo Garcia, L, Lin, P, Mohanty, V, Kim, KH, Jiang, XL, Pan, Y, Li, YE, Liu, B, Nunez Cortes, Ak, Zhang, C, Fathi, M, Rezvan, A, Montalvo, MJ, Cha, SL, Reyes Silva, F, Shrestha, R, Guo, X, Kundu, K, Biederstädt, A, Muniz-Feliciano, L, Deyter, GM, Kaplan, M, Jiang, XR, Liu, E, Jain, A, Roszik, J, Fowlkes, NW, Solis Soto, LM, Raso, G, Khoury, J, Lin, P, Vega Vazquez, F, Varadarajan, N, Chen, K, Marin, D, Shpall, E, Rezvani, K. CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ ZAP70 Signaling Axis. Cancer discovery 14(10):1879-1900, 2024. e-Pub 2024. PMID: 38900051.
- Kumar, B, Singh, A, Basar, R, Uprety, N, Li, YE, Fan, H, Nunez Cortes, Ak, Kaplan, M, Acharya, S, Shaim, H, Xu, AC, Wu, M, Ensley, E, Fang, D, Banerjee, PP, Melo Garcia, L, Tiberti, S, Lin, P, Rafei, H, Munir, MN, Moore, M, Shanley, M, Mendt Vilchez, MC, Kerbauy, LN, Liu, B, Biederstädt, A, Gokdemir, E, Ghosh, S, Kundu, K, Reyes Silva, F, Jiang, XR, Wan, X, Gilbert, AL, Dede, M, Mohanty, V, Dou, J, Zhang, P, Liu, E, Muniz-Feliciano, L, Deyter, GM, Jain, A, Rodriguez-Sevilla, JJ, Colla, S, Garcia-Manero, G, Shpall, E, Chen, K, Abbas, HA, Rai, K, Rezvani, K, Daher, M. BATF is a major driver of NK cell epigenetic reprogramming and dysfunction in AML. Science translational medicine 16(764), 2024. e-Pub 2024. PMID: 39259809.
- Shanley, M, Daher, M, Dou, J, Li, S, Basar, R, Rafei, H, Dede, M, Gumin, J, Pantaleόn Garcίa, J, Nunez Cortes, AK, He, S, Jones, C, Acharya, S, Fowlkes, NW, Xiong, D, Singh, S, Shaim, H, Hicks, SC, Liu, B, Jain, A, Zaman, MF, Miao, Q, Li, YE, Uprety, N, Liu, E, Muniz-Feliciano, L, Deyter, GM, Mohanty, V, Zhang, P, Evans, S, Shpall, EJ, Lang Jr, FF, Chen, K, Rezvani, K. Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD. Cancer cell 42(8):1450-1466.e11, 2024. e-Pub 2024. PMID: 39137729.
- Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1/2 trial. Nat Med 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
- Li L, Mohanty V, Dou J, Huang Y, Banerjee PP, Miao Q, Lohr JG, Vijaykumar T, Frede J, Knoechel B, Muniz-Feliciano L, Laskowski TJ, Liang S, Moyes JS, Nandivada V, Basar R, Kaplan M, Daher M, Liu E, Li Y, Acharya S, Lin P, Shanley M, Rafei H, Marin D, Mielke S, Champlin RE, Shpall EJ, Chen K, Rezvani K. Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering. Sci Adv 9(30):eadd6997, 2023. e-Pub 2023. PMID: 37494448.
- Imahashi N, Basar R, Huang Y, Wang F, Baran N, Banerjee PP, Lu J, Nunez Cortes AK, Uprety N, Ensley E, Muniz-Feliciano L, Laskowski TJ, Moyes JS, Daher M, Mendt M, Kerbauy LN, Shanley M, Li L, Lim FLWI, Shaim H, Li Y, Konopleva M, Green M, Wargo J, Shpall EJ, Chen K, Rezvani K. Activated B cells suppress T-cell function through metabolic competition. J Immunother Cancer 10(12), 2022. e-Pub 2022. PMID: 36543374.
- Li Y, Basar R, Wang G, Liu E, Moyes JS, Li L, Kerbauy LN, Uprety N, Fathi M, Rezvan A, Banerjee PP, Muniz-Feliciano L, Laskowski TJ, Ensley E, Daher M, Shanley M, Mendt M, Acharya S, Liu B, Biederstadt A, Rafei H, Guo X, Melo Garcia L, Lin P, Ang S, Marin D, Chen K, Bover L, Champlin RE, Varadarajan N, Shpall EJ, Rezvani K. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat Med 28(10):2133-2144, 2022. e-Pub 2022. PMID: 36175679.
- . Trogocytosis-mediated tumor relapse after CAR-NK cell therapy prevented by inhibitory CARs. Nat Med 28(10):2013-2014, 2022. e-Pub 2022. PMID: 36175680.
- Basar R, Uprety N, Ensley E, Daher M, Klein K, Martinez F, Aung F, Shanley M, Hu B, Gokdemir E, Nunez Cortes AK, Mendt M, Reyes Silva F, Acharya S, Laskowski T, Muniz-Feliciano L, Banerjee PP, Li Y, Li S, Melo Garcia L, Lin P, Shaim H, Yates SG, Marin D, Kaur I, Rao S, Mak D, Lin A, Miao Q, Dou J, Chen K, Champlin RE, Shpall EJ, Rezvani K. Generation of glucocorticoid-resistant SARS-CoV-2 T cells for adoptive cell therapy. Cell Rep 36(3):109432, 2021. e-Pub 2021. PMID: 34270918.
- Shaim H, Shanley M, Basar R, Daher M, Gumin J, Zamler DB, Uprety N, Wang F, Huang Y, Gabrusiewicz K, Miao Q, Dou J, Alsuliman A, Kerbauy LN, Acharya S, Mohanty V, Mendt M, Li S, Lu J, Wei J, Fowlkes NW, Gokdemir E, Ensley EL, Kaplan M, Kassab C, Li L, Ozcan G, Banerjee PP, Shen Y, Gilbert AL, Jones CM, Bdiwi M, Nunez-Cortes AK, Liu E, Yu J, Imahashi N, Muniz-Feliciano L, Li Y, Hu J, Draetta G, Marin D, Yu D, Mielke S, Eyrich M, Champlin RE, Chen K, Lang FF, Shpall EJ, Heimberger AB, Rezvani K. Targeting the alphav integrin/TGF-beta axis improves natural killer cell function against glioblastoma stem cells. J Clin Invest 131(14), 2021. e-Pub 2021. PMID: 34138753.
- Li Y, Cook KL, Yu W, Jin L, Bouker KB, Clarke R, Hilakivi-Clarke L. Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor. Nutrients 13(5), 2021. e-Pub 2021. PMID: 34069442.
- Daher M, Basar R, Gokdemir E, Baran N, Uprety N, Nunez Cortes AK, Mendt M, Kerbauy LN, Banerjee PP, Shanley M, Imahashi N, Li L, Lim FLWI, Fathi M, Rezvan A, Mohanty V, Shen Y, Shaim H, Lu J, Ozcan G, Ensley E, Kaplan M, Nandivada V, Bdiwi M, Acharya S, Xi Y, Wan X, Mak D, Liu E, Jiang XR, Ang S, Muniz-Feliciano L, Li Y, Wang J, Kordasti S, Petrov N, Varadarajan N, Marin D, Brunetti L, Skinner RJ, Lyu S, Silva L, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Li H, Fowlkes NW, Chen K, Konopleva M, Champlin RE, Shpall EJ, Rezvani K. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood 137(5):624-636, 2021. e-Pub 2021. PMID: 32902645.
- Liu E, Ang SOT, Kerbauy L, Basar R, Kaur I, Kaplan M, Li L, Tong Y, Daher M, Ensley EL, Uprety N, Nunez Cortes AK, Yang RZ, Li Y, Shaim H, Reyes Silva F, Lin P, Mohanty V, Acharya S, Shanley M, Muniz-Feliciano L, Banerjee PP, Chen K, Champlin RE, Shpall EJ, Rezvani K. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Front Immunol 12:626098, 2021. e-Pub 2021. PMID: 33717142.
- Mendt M, Daher M, Basar R, Shanley M, Kumar B, Wei Inng FL, Acharya S, Shaim H, Fowlkes N, Tran JP, Gokdemir E, Uprety N, Nunez-Cortes AK, Ensley E, Mai T, Kerbauy LN, Melo-Garcia L, Lin P, Shen Y, Mohanty V, Lu J, Li S, Nandivada V, Wang J, Banerjee P, Reyes-Silva F, Liu E, Ang S, Gilbert A, Li Y, Wan X, Gu J, Zhao M, Baran N, Muniz-Feliciano L, Wilson J, Kaur I, Gagea M, Konopleva M, Marin D, Tang G, Chen K, Champlin R, Rezvani K, Shpall EJ. Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. Front Immunol 12:631353, 2021. e-Pub 2021. PMID: 34017325.
- Basar R, Daher M, Uprety N, Gokdemir E, Alsuliman A, Ensley E, Ozcan G, Mendt M, Hernandez Sanabria M, Kerbauy LN, Nunez Cortes AK, Li L, Banerjee PP, Muniz-Feliciano L, Acharya S, Fowlkes NW, Lu J, Li S, Mielke S, Kaplan M, Nandivada V, Bdaiwi M, Kontoyiannis AD, Li Y, Liu E, Ang S, Marin D, Brunetti L, Gundry MC, Turk R, Schubert MS, Rettig GR, McNeill MS, Kurgan G, Behlke MA, Champlin R, Shpall EJ, Rezvani K. Large-scale GMP-compliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirus-specific T cells. Blood Adv 4(14):3357-3367, 2020. e-Pub 2020. PMID: 32717029.
- Li L, Chen H, Marin D, Xi Y, Miao Q, Lv J, Banerjee PP, Shaim H, Daher M, Basar R, Imahashi N, Jimenez J, Hu B, Mehta RS, Kerbauy LN, Kaplan M, Mendt M, Ozcan G, Gokdemir E, Hernandez Sanabria M, Li Y, Chen K, Wang J, Muniz-Feliciano L, Zhao WL, Champlin RE, Shpall EJ, Rezvani K. A novel immature natural killer cell subpopulation predicts relapse after cord blood transplantation. Blood Adv 3(23):4117-4130, 2019. e-Pub 2019. PMID: 31821460.
- Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. Cell Stem Cell 23(2):181-192.e5, 2018. e-Pub 2018. PMID: 30082067.
- Li Y, Jin L, Ye F, Ma Q, Yang Z, Liu D, Yang J, Ma D, Gao Q. Isoform expression patterns of EPHA10 protein mediate breast cancer progression by regulating the E-Cadherin and beta-catenin complex. Oncotarget 8(18):30344-30356, 2017. e-Pub 2017. PMID: 28427223.
Review Articles
- Li Y, Rezvani K, Rafei H. Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer. Immunol Rev 320(1):217-235, 2023. e-Pub 2023. PMID: 37548050.
- Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunology 10(4):e1274, 2021. e-Pub 2021. PMID: 33959279.
- Zhu H, Lai YS, Li Y, Blum RH, Kaufman DS. Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy. Stem Cells 36(2):134-145, 2018. e-Pub 2018. PMID: 29235195.
Other Articles
- Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to. Nature medicine 31(8):2816, 2025. PMID: 40571757.
Patient Reviews
CV information above last modified July 22, 2026